BIIB FY 2024 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

FY 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$9.7B-1.6% YoY

Gross Profit

$7.4B76.1% margin

Operating Income

$2.5B25.7% margin

Net Income

$1.6B16.9% margin

EPS (Diluted)

$11.19

Cash Flow

Operating Cash Flow

$2.9B

Free Cash Flow

$2.5B

Stock-Based Comp.

$291M

Balance Sheet

Total Assets

$28.0B

Total Liabilities

$11.3B

Stockholders' Equity

$16.7B

Cash & Equivalents

$2.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9.7B	$9.8B	-1.6%
Gross Profit	$7.4B	$7.3B	+0.9%
Operating Income	$2.5B	$2.1B	+18.7%
Net Income	$1.6B	$1.2B	+40.6%